GlassScriptPhysician profile
Aminata Dieng
NPI 1881081784
$3,557.61
in general payments reported to CMS, 2019-2025
37 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $154 · 2022: $2,318 · 2023: $638 · 2024: $322 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,025 · Education: $60.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,024.60 |
| Education | $60.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $387.94 | 2022-2023 | Padcev |
| Astrazeneca Pharmaceuticals LP | $315.55 | 2021-2023 | Lokelma |
| Amgen INC. | $238.34 | 2021-2025 | Krystexxa |
| Merck Sharp & Dohme LLC | $224.84 | 2022 | |
| Celgene Corporation | $201.79 | 2022-2023 | Pomalyst, Reblozyl |
| Janssen Biotech, INC. | $182.34 | 2022 | |
| Lilly USA, LLC | $179.60 | 2022 | |
| Eisai INC. | $166.76 | 2022 | |
| Incyte Corporation | $150.32 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $131.65 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $122.92 | 2022-2023 | Opdivo |
| Astellas Pharma US INC | $99.95 | 2022 | |
| Aurinia Pharma U.S., INC. | $99.08 | 2022-2024 | Lupkynis |
| Abbvie INC. | $99.00 | 2022 | |
| Fresenius USA Marketing, INC. | $98.75 | 2021-2024 | Velphoro |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aminata Dieng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.